Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 19/20 | 1.00 |
| ▸ | HDAC3 | O15379 | 15/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 15/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 14/20 | 1.00 |
| ▸ | HDAC10 | Q969S8 | 13/20 | 1.00 |
| ▸ | HDAC8 | Q9BY41 | 13/20 | 1.00 |
| ▸ | HDAC4 | P56524 | 12/20 | 1.00 |
| ▸ | HDAC7 | Q8WUI4 | 12/20 | 1.00 |
| ▸ | HDAC11 | Q96DB2 | 12/20 | 1.00 |
| ▸ | HDAC9 | Q9UKV0 | 12/20 | 1.00 |
| ▸ | HDAC5 | Q9UQL6 | 12/20 | 1.00 |
| ▸ | NCOR2 | Q9Y618 | 4/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13783983 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC10 | |
| SCHEMBL3380925 | 1.00 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC10 | |
| SCHEMBL3383553 | 0.92 | HDAC3 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC10 | |
| Hydrochloric Acid SCHEMBL3383189 | 0.90 | HDAC1 (0.91) | HDAC1HDAC3HDAC2HDAC6HDAC10 | |
| SCHEMBL3381728 | 0.89 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC10 | |
| SCHEMBL3383398 | 0.89 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC10 | |
| SCHEMBL3379584 | 0.87 | HDAC1 (0.77) | HDAC1HDAC3HDAC2HDAC6HDAC10 | |
| SCHEMBL3383965 | 0.87 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC6HDAC10 | |
| SCHEMBL13784600 | 0.87 | HDAC3 (0.80) | HDAC1HDAC3HDAC2HDAC6HDAC10 | |
| SCHEMBL16016612 | 0.86 | HDAC1 (0.84) | HDAC1HDAC3HDAC2HDAC6HDAC10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280764-B1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2010-11-24 | — | — | EP | disclosed |
| US-20090181971-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090181971-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. | 2009-07-16 | — | — | US | disclosed |
| US-20090181971-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. | 2009-07-16 | — | — | US | disclosed |
| US-7288567-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2007-10-30 | — | — | US | disclosed |
| US-7288567-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2007-10-30 | — | — | US | disclosed |
| EP-1524262-A1 | Inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2005-04-20 | — | — | EP | disclosed |
| EP-1280764-A2 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2003-02-05 | — | — | EP | disclosed |
| US-20020115826-A1 | Inhibitors of histone deacetylase | 92229129 QUEBEC INC. (CA) | 2002-08-22 | — | — | US | disclosed |
| WO-2001070675-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115826-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | HDAC1 1/4885HDAC3 3/4885HDAC2 5/4885 |
| US-20090181971-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | HDAC1 1/4885HDAC3 3/4885HDAC2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.